Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Troxatyl

 
National Institutes of Health

Related topics

Related topics

2 relations
BCH 4556

Broader (1)

troxacitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Chronic myelogenous leukemia.
Chronic myelogenous leukemia (CML) is a malignant hematopoietic stem cell disorder characterized by the Philadelphia chromosome… Expand
2007
2007
Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer
BackgroundGemcitabine, a deoxycytidine nucleoside analog, is the current standard chemotherapy used as first-line treatment for… Expand
  • table 1
  • table 3
  • table 4
  • figure 2
  • figure 3
2005
2005
Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.
BACKGROUND Troxacitabine (Troxatyl) is a novel L-enantiomer nucleoside analog with activity in pancreatic cancer xenograft models… Expand
  • table 1
  • table 2
2003
2003
Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells
PurposeTroxacitabine (BCH-4556, l-(−)-OddC, Troxatyl) is a novel β-l-nucleoside analogue with potent antineoplastic activity both… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2003
2003
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
PURPOSE A multi-institution phase II study was undertaken by National Cancer Institute of Canada-Clinical Trials Group to… Expand
2002
2002
Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts
Abstract Purpose. We have recently identified a deoxycytidine nucleoside analogue, troxacitabine (β-L-dioxolane cytidine… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2002
2002
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
PURPOSE Troxacitabine (Troxatyl, BCH-4556; BioChem Pharma Inc, Basingstoke, United Kingdom) is a novel synthetic L-nucleoside… Expand
Review
2002
Review
2002
Troxacitabine-based therapy of refractory leukemia
  • F. Giles
  • Expert review of anticancer therapy
  • 2002
    • Corpus ID: 42920941
Unique among currently approved or in-development nucleoside analogs, troxacitabine (Troxatyl™) is an L-nucleoside with… Expand
Highly Cited
2001
Highly Cited
2001
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Troxacitabine (Troxatyl; BCH-4556; (-)-2'-deoxy-3'-oxacytidine), a deoxycytidine analogue with an unusual dioxolane structure and… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2000
2000
Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity
Abstract.Purpose: Troxacitabine (β-L-dioxolane cytidine, BCH-4556; Troxatyl, BioChem Pharma Inc.) is a novel nucleoside analogue… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE